Cancer

Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate

Differentiated resistance profile positions Traws’ program as a potential class leaderNEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Traws Pharma,…

2 years ago

GeneType and Humanise Health host “Know Your Risk” Event

PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader…

2 years ago

Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement

All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V:…

2 years ago

Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium

PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium…

2 years ago

Spago Nanomedical Receives Declarations of Intent from the Largest Owner, Board and Management Team Regarding the Exercise of TO12

LUND, SWEDEN / ACCESSWIRE / May 23, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the…

2 years ago

Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries

The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to expand access to immuno-oncology therapy Opdivo™…

2 years ago

Halberd/Athena GTX Research Promises a Much Brighter Future

Walt Disney once said, "All our dreams can come true if we have the courage to pursue them".JACKSON CENTER, PA…

2 years ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDTCAMBRIDGE, MA / ACCESSWIRE /…

2 years ago

Veru to Present at the Jefferies Global Healthcare Conference

MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 years ago

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds…

2 years ago